GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care - PubMed

14 hours ago

GOLD 2026 introduces updates to COPD management, emphasizing early diagnosis, multi-dimensional assessment, and personalized treatment.
Key innovations include recognizing disease activity as a therapeutic target and refining the ABE classification with a lower threshold for exacerbation-prone patients.
Nonpharmacologic interventions like pulmonary rehabilitation, vaccination, and smoking cessation are elevated to core disease-modifying strategies.
Pharmacological escalation starts with dual bronchodilation, with further intensification to biomarker-guided triple therapy for selected patients.
Biologics such as dupilumab and mepolizumab are introduced as add-on therapy for exacerbation-prone eosinophilic COPD.
Artificial intelligence and digital technologies are recognized as promising adjuncts, though clinical implementation remains preliminary.
GOLD 2026 advances precision medicine in COPD but highlights ongoing limitations in efficacy, cost effectiveness, and equitable access to interventions.

Hasty Briefsbeta